Greylin Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Greylin Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$966K	Buy	+9,050	New	+$995K	0.16%	46
2023 Q1	–	Sell	-1,392	Closed	-$222K	–	74
2022 Q4	$222K	Sell	1,392 -686	-33%	-$101K	0.04%	65
2022 Q3	$277K	Sell	2,078 -2,105	-50%	-$320K	0.06%	61
2022 Q2	$653K	Sell	4,183 -157	-4%	-$24.2K	0.13%	48
2022 Q1	$676K	Buy	4,340 +846	+24%	+$123K	0.12%	52
2021 Q4	$445K	Buy	3,494 +1,252	+56%	+$165K	0.08%	68
2021 Q3	$292K	Buy	2,242 +852	+61%	+$129K	0.06%	82
2021 Q2	$247K	Buy	+1,390	New	+$241K	0.05%	87

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Greylin Investment Management's JAZZ Position: Q2 2024 in Review

Greylin Investment Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2024: 9,050 shares worth $966K. The stake represents 0.16% of the portfolio and ranks #46 among its holdings. This is a return to the name: Greylin Investment Management previously reported a position in JAZZ as recently as Q4 2022.

Greylin Investment Management first reported a position in JAZZ in Q2 2021 and has held it in 8 quarters since. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Greylin Investment Management held 9,050 shares of Jazz Pharmaceuticals worth $966K as of Q2 2024.
Jazz Pharmaceuticals was a new Greylin Investment Management position in Q2 2024.
Jazz Pharmaceuticals made up 0.16% of Greylin Investment Management's portfolio in Q2 2024, its #46 holding.
Greylin Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Greylin Investment Management's 13F filing for Q2 2024, filed 19 Jul 2024.